Nexstim Plc (Nexstim) is a medical technology company that specializes in non-invasive brain stimulation technology. The company operates in the international market, focusing on diagnostics and therapy for neurosurgery, major depressive disorder, and chronic neuropathic pain. The company operates through its subsidiaries in the US and Germany and has delivered over 260 diagnostic systems and over 130 therapy systems worldwide. Nexstim's business portfolio includes diagnostics and therapy solutions using navigated transcranial magnetic stimulation (nTMS) technology. The diagnostics business focuses on presurgical mapping of the brain's speech and motor cortices, with systems approved by the FDA and CE-marked. The therapy business offers treatment options for major depressive disorder and chronic unilateral neuropathic pain, also with FDA and CE approvals. The company's technology uses advanced 3D navigation and algorithms to provide accurate brain stimulation tailored to each patient's neurophysiological readings. Customers can choose systems with either diagnostic or therapy functionalities or a combination of both.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.